441O Preliminary safety and clinical activity of erlotinib plus atezolizumab from a Phase Ib study in advanced NSCLC
暂无分享,去创建一个
C. Rudin | S. Gettinger | R. Heist | D. Costa | P. Schmid | B. Ma | A. Dowlati | B. Besse | V. Villaflor | A. Cervantes | C. O’Hear | P. Foster | I. Sarkar | M. Huseni | C. O'Hear | Indrani Sarkar